Medtronic (NYSE:MDT) announced today that it received CE Mark approval in Europe for its MiniMed 790G next-generation insulin pump.
The closed-loop insulin pump system is indicated for treating Type 1 diabetes in people aged 70 to 80 years old. It uses Medtronic’s SmartGuard algorithm to automate the delivery of basal insulin and correction boluses every five minutes.